Abstract:Kuo-Tung Hung, 1 Shih-Cheng Yang, 1 Cheng-Kun Wu, 1, 2 Hsing-Ming Wang, 1 Chih-Chien Yao, 1 Chih-Ming Liang, 1, 2 Wei-Chen Tai, 1, 2 Keng-Liang Wu, 1, 2 Yuan-Hung Kuo, 1, 2 Chen-Hsiang Lee, 2, 3 Seng-Kee Chuah 1, 2 1 Division of Hepatogastroenterology, Department of Internal Medicine, Chang Gung Memorial Hospital, Kaohsiung, Taiwan; 2 Chang Gung University, College of Medicine, Taoyuan, Taiwan; 3 Division of Infectious Disease, Department of Internal Medicine, Chang Gung Memorial Hospital, Kaohsiung, Taiwan Correspondence: Seng-Kee Chuah; Chih-Ming Liang Division of Hepatogastroenterology, Chang Gung Memorial Hospital, 123, Ta-Pei Road, Niao-Sung Hsiang, Kaohsiung, 833, Taiwan Tel + 886-7-7317123 ext. 8301 Fax + 886-7-7322402 Email chuahsk@seed.net.tw; gimy54861439@gmail.com Purpose: Non-bismuth concomitant quadruple therapy is commonly administered in Taiwan, achieving an acceptable efficacy as a first-line anti -Helicobacter pylori treatment. This study compared the eradication rates between esomeprazole- and lansoprazole-based non-bismuth concomitant quadruple therapy for first-line anti- H. pylori treatment. Patients and Methods: This study included 206 H. pylori -infected naïve patients between July 2016 and February 2019. The patients were prescribed with either a 7-day non-bismuth containing quadruple therapy (esomeprazole, 40 mg twice daily; amoxicillin, 1 g twice daily; and metronidazole, 500 mg twice daily; and clarithromycin, 500 mg twice daily for 7 days [EACM group]; lansoprazole, 30 mg twice daily; amoxicillin, 1 g twice daily; metronidazole, 500 mg twice daily; and clarithromycin, 500 mg twice daily [LACM group]). Then, the patients were asked to perform urea breath tests 8 weeks later. Results: The eradication rates in the EACM group were 86.1% (95% confidence interval [CI], 77.8%– 92.2%) and 90.6% (95% CI, 82.9%– 95.6%) in the intention-to-treat (ITT) and the per-protocol (PP) analyses, respectively. Moreover, the eradication rates in the LACM group were 90.1% (95% CI, 82.6%– 95.2%) and 92.6% (95% CI, 85.5%– 96.9%) in the ITT and the PP analyses, respectively. Consequently, the LACM group exhibited more diarrhea patients than the EACM group (7.1% versus 1.0%, p = 0.029), but all symptoms were mild. Univariate analysis in this study showed that metronidazole-resistant strains were the clinical factor affecting the eradications (95.3% versus 78.9%, p = 0.044). Moreover, a trend was observed in dual clarithromycin- and metronidazole-resistant strains (91.5% versus 66.7%, p = 0.155). Conclusion: The eradication rates between esomeprazole and lansoprazole-based non-bismuth concomitant quadruple therapy for first-line H. pylori treatment were similar in this study. Both could achieve a > 90% report card in the PP analysis. Keywords: Helicobacter pylori , esomeprazole, lansoprazole, concomitant therapy, antibiotic resistance

Esomeprazole regimens for reflux symptoms in Chinese patients with chronic gastritis

Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.

Quadruple Therapy with Vonoprazan 20 Mg Daily As a First-Line Treatment for Helicobacter Pylori Infection: A Single-Center, Open-Label, Noninferiority, Randomized Controlled Trial.

Effect of Esomeprazole and Rabeprazole on Intragastric Ph in Healthy Chinese: an Open, Randomized Crossover Trial

Quality of Life and Cost-Effectiveness of Combined Therapy for Reflux Esophagitis.

Clinicai Investigation on Esomeprazoie Treatment of Sixty-Nine Asthmatic Patients with Gastroesophageal Reflux Symptoms

Vonoprazan 10 mg or 20 mg vs. lansoprazole 15 mg as maintenance therapy in Asian patients with healed erosive esophagitis: A randomized controlled trial

The Prevention of Upper Gastrointestinal Bleeding in Seriously Ill Chinese Patients: A Randomised, Double-Blind Study Evaluating Esomeprazole Vs Cimetidine

Prevention of upper gastrointestinal bleeding in critically ill Chinese patients: a randomized, double-blind study evaluating esomeprazole and cimetidine

<TITLE>COMPARATIVE EFFECTS OF ESOMEPRAZOLE AND OMEPRAZOLE IN TREATING REFLUX ESOPHAGITIS OF THE AGED

Risk Factors for Gastroesophageal Reflux Disease, Reflux Esophagitis and Non-Erosive Reflux Disease among Chinese Patients Undergoing Upper Gastrointestinal Endoscopic Examination

Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice

Gastroesophageal Reflux Disease Questionnaire (gerdq) in Real‐world Practice: A National Multicenter Survey on 8065 Patients

Modified Xiaochaihu Decoction for gastroesophageal reflux disease: A randomized double-simulation controlled trial

Behavior Intervention Therapy in Patients with Gastroesophageal Reflux Disease

Optimized Dual Therapy for Treatment‐naive Patients of Helicobacter Pylori Infection: A Large‐scale Prospective, Multicenter, Open‐label, Randomized Controlled Study

Survey of nocturnal reflux in patients with gastroesophageal reflux disease in China.

[Clinical trial of gastroesophageal reflux disease with the disharmony between liver and stomach syndrome treated with acupuncture regulating qi based on the compatibility of the five meridians]

Chronic gastritis in China: a national multi-center survey

Pharmacogenetics of Esomeprazole or Rabeprazole-Based Triple Therapy in Helicobacter Pylori Eradication in Hong Kong Non-Ulcer Dyspepsia Chinese Subjects

Protocol of a Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Probiotics on the Gut Microbiome of Patients with Gastro-Oesophageal Reflux Disease Treated with Rabeprazole.